Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases.
about
Treatment of juvenile idiopathic arthritis: a revolution in careClinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adultsAdult-onset Still's disease with disseminated intravascular coagulation and multiple organ dysfunctions dramatically treated with cyclosporine AMacrophage activation syndrome in juvenile rheumatoid arthritis successfully treated with cyclosporine A: a case reportMacrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients.Histiocytic glomerulopathy associated with macrophage activation syndrome.Macrophage Activation Syndrome.Macrophage activation syndrome in a patient with systemic onset of the juvenile idiopathic arthritis.2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening aThe treatment of juvenile arthritis.Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis.Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantationAutologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidityModern management of children with haemophagocytic lymphohistiocytosis.Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis.Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.Macrophage activation syndrome and other systemic inflammatory conditions after BMT.Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis.Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication?Association of Macrophage Activating Syndrome with Castleman's Syndrome in Systemic Lupus Erythematosus.Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease.Pediatric hemophagocytic syndromes: a diagnostic and therapeutic challengeMacrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review.Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis.Macrophage activation syndrome and cytokine-directed therapies.Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.Macrophage activation syndrome in the era of biologic therapy.The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era.An Unexpected Fever Post Serogroup B Meningococcal Sepsis.Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.Oral low-dose tacrolimus therapy for refractory hemophagocytic syndrome associated with systemic lupus erythematosus.Management of severe neutropenia with cyclosporin during initial treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis.Leukemia Inhibitory Factor-Loaded Nanoparticles with Enhanced Cytokine Metabolic Stability and Anti-Inflammatory Activity.Clinical Manifestations of Kawasaki Disease Shock Syndrome.Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis.
P2860
Q26849497-53175C78-DC9E-472A-8D7F-1B43521A9F41Q26852503-6139564A-E3EC-4CD8-ABCA-3E6EBDE9E7C8Q28167268-5F177BB7-8D75-437B-BFFE-413FA225E7EFQ28213004-7789A1A4-7D4F-4849-B08B-2872E77DFCC2Q33386883-AB474C5A-2455-401A-A41A-3CAECC9137CFQ33421490-266462D4-3FDF-453E-8534-4856AD1DD9CAQ33426151-C76D627E-163C-406F-9802-4B035E56604CQ33433845-C28C6764-B69A-444A-83C7-2BA4316A860EQ33613293-2603FDDE-5011-4086-BB07-3014E9E298FCQ34388561-AF21D137-2343-4A1D-8965-8F5338047128Q35204115-FD765E76-14D7-422B-855A-603F6F8EAA61Q35552384-59895BED-6263-4BA6-B747-D610728AB2EAQ35553325-AF4D321C-9E05-4E7C-A3DA-64D3900BAB07Q35607712-4274E470-95C8-4C1C-8BBF-0F98EFDDB488Q36245985-39B89FB6-FE77-4955-ACAB-4B8FF48C6815Q36346681-C29FC71C-9662-436F-A333-8858033F6449Q36406434-77F32AB6-37A1-40A5-826E-38BD62284D76Q36617892-F0B4CE4D-D814-4D06-AA58-91BA2BE0CB6DQ36915642-7698C37B-C4AA-4012-A8B0-3818EB8B6289Q37365205-507FAAEE-6596-491A-B57F-2DE54C81C763Q37488637-D4541634-ED4D-4D68-BEA5-A9231AB853F5Q37763298-FBF7F9A3-F988-49F4-B1F7-1C09A8F6C0C5Q37993678-47E453DD-BF0B-48AD-89A0-7C7EC8C55CBBQ38088660-5FECE18C-82FF-406D-A71B-7D78FC6D1257Q38161412-D861FCBE-0162-4907-A849-0D2BAA0F2765Q38224085-31515AEE-E0AC-415A-9C14-889D32879BD1Q38267068-34635F5E-CEE5-4103-9DF3-63E57360CCD0Q38406386-EF35226E-9822-4F11-A805-06190F092D56Q38665824-1E3C39B4-43AC-43AB-B95E-C31F82A661CFQ38672339-83D6F902-30CC-41A4-B75F-5B025F3B55DFQ38786756-C529CEC4-8A61-4A88-9475-FDA8C83F32BFQ38925320-351F59F7-140A-4622-A12A-1FDAE6417C27Q39144075-8F4C8F56-32F0-4738-801A-25EC672F5CC5Q40075965-5A8A15A0-40DF-4EBF-B2D1-603153614FCEQ40198507-68CA838D-B456-4D7B-B62F-4DC171FF02CCQ40319856-D4FDF97F-827F-4575-AEA3-9A8E792C4A16Q45744447-5F1EB569-362B-4297-9C76-281D135472B2Q47755745-2454FDE8-8B5B-432B-8349-38B96513C1A1Q47804715-48664B62-5456-4615-9D86-F3E7549C2417Q47931407-09C46BBC-A37D-4426-8FBB-4A1FFE9F41C4
P2860
Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Efficacy of cyclosporine A in ...... thritis: report of five cases.
@en
type
label
Efficacy of cyclosporine A in ...... thritis: report of five cases.
@en
prefLabel
Efficacy of cyclosporine A in ...... thritis: report of five cases.
@en
P2093
P1476
Efficacy of cyclosporine A in ...... thritis: report of five cases.
@en
P2093
P304
P356
10.1016/S0022-3476(96)70160-9
P407
P50
P577
1996-11-01T00:00:00Z